WuXi XDC

Bispecific Antibody-Drug Conjugates (BsADCs): The Next Frontier in Targeted Therapy Bispecific antibody-drug conjugates (BsADCs) are transforming the landscape of targeted therapy by merging the dual-targeting precision of bispecific antibodies with the potent payload delivery of antibody-drug conjugates (ADCs). By simultaneously binding to two distinct antigens or epitopes, BsADCs offer a revolutionary strategy to address resistance mechanisms often seen in single-target therapies. This innovative approach not only enhances therapeutic precision but also significantly improves treatment efficacy. ?? Explore this cutting-edge field in greater detail with our latest slide deck, which delves into the mechanisms, market landscape, and WuXi XDC’s pivotal role in driving BsADC innovation. Learn how we are at the forefront of shaping the future of targeted therapies. ?? Access the slide deck here: https://lnkd.in/gJFVTdXG

WuXi XDC Cayman Inc. (the “WuXi XDC” or the “Group”, stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate market, is pleased to announce its annual results for 2024 (the “Reporting Period”). ? - Revenue increased by 90.8% YoY to RMB 4,052 million - Gross profit grew by 121.6% YoY to RMB 1,240 million, with its margin of 30.6%, a 4.3 percentage points increase compared to that of 2023 - Net profit surged by 277.2% YoY to RMB 1,070 million, with its margin of 26.4%, a 13.0 percentage points increase compared to that of 2023 - The total global customer base expanded to 499, adding 154 new customers in 2024 - The total number of iCMC projects reached 194, adding 53 new iCMC projects to the portfolio - The total backlog grew to US$991 million, representing a 71.3% YoY growth - Launched a new production line, BCM2 Line 2, at the Wuxi site, further increased manufacturing capacities - The construction of Singapore commercial site is progressing smoothly and well on track for operation commencement by the end of 2025 - Winner of the “Best CDMO” Award consecutively in 2023 and 2024 - Continue to invest in frontier technology, solidifying the Group’s competitiveness and leadership position Dr. Jimmy Li, CEO of WuXi XDC, stated, “The year 2024 has been another year of exceptional growth and remarkable achievements for us, even as we navigated a dynamic macro environment. Our strong performances reflect the relentless dedication of our entire organization, as well as the trust and support from our customers, investors, and stakeholders. We have made significant strides in expanding our global presence, enhancing our in-house technology capabilities, and solidifying our position as a leading CRDMO in the ADC and bioconjugate market. Our focus on customer needs and innovative trends has driven our success, enabling us to deliver high-quality services and solutions. The Singapore commercial site is on track and to be operational by the end of 2025, underscoring our unwavering commitment to a robust global presence by delivering top-tier commercial manufacturing capabilities. Looking ahead, we are excited by the vast market opportunities in the bioconjugate space. We believe that with our strong expertise and integrated capabilities, we will continue to win customers, and increase our market share going forward.” More detailed information about this collaboration is available from the following link. https://shorturl.at/7ERlv

4 月 9 日から 11 日まで東京で開催される CPHI Japan にぜひご参加ください。WuXi XDC のペイロード?リンカーのプロセス開発および製造部門責任者であるDr Xudong Wei上級副社長が、4 月 9 日に「薬物複合体の開発に向けたペイロード?リンカーの合成：CMC戦略で成功するための重要な要素」と題する洞察に富んだプレゼンテーションを行います。Dr Xudong Weiは、薬物複合体にとって重要なペイロード - リンカーの合成、およびCMC戦略で成功するための詳細で実践的な知識を共有します。 皆様とお会いできることを楽しみにしています。チャットの日程を調整しましょう：https://lnkd.in/guvvwrnY #CPHI #payload #linker #conjugate #conjugates #bioconjugation #bioconjugate #bioconjugates #adc #adcs #antibodydrugcongugate #antibodydrugcongugates #cmc #cdmo #crdmo #biomanufacturing #bioprocessing

Tackling the complex druggability maze of XDC drugs? Our upcoming webinar is your compass! https://lnkd.in/gYv8Cnyw On March 27th, Dr. Jingjie Huang will deliver an exclusive webinar "Bridging ‘Small’ Molecules with ‘Big’ Molecules: Accelerating ADCs & XDCs Discovery and Development with Novel Linker Technologies." Join us to discover breakthrough linker technologies that can modulate physicochemical properties of ADCs & XDCs to enhance druggability and accelerate the discovery and development timelines! ?? Webinar: Bridging “Small” Molecules with “Big” Molecules: Accelerating ADCs & XDCs Discovery and Development with Novel Linker Technologies ?? Speaker: Dr. Jingjie Huang, Head of Payload-Linker Discovery Service, WuXi XDC ?? March 27, 11:00 AM EDT, 4:00 PM CET Final chance to register! Don’t miss this opportunity to gain transformative insights from a leading expert！ #linker #conjugate #conjugates #bioconjugation #bioconjugate #bioconjugates #adc #adcs #antibodydrugcongugate #antibodydrugcongugates #cmc #cdmo #crdmo #biomanufacturing #bioprocessing

From library screening and leads generation to preclinical candidate (PCC) selection, we provide tailored linker-payload optimization and selection services to advance your path to success. Learn more: https://lnkd.in/gMqxP3Gb #bioconjugation #biomanufacturing #biopharma #biologics #biotherapeutics #ADC #antibodydrugconjugate #Payload #Payloadlinker

?? Reflecting on the 2025 SAPA-GP Annual Conference! The 2025 SAPA-GP (Sino-American Pharmaceutical Professionals Association -Greater Philadelphia) Annual Conference has come to a successful close, and we are grateful to have been part of this dynamic and inspiring event. It was an honor to connect with a diverse group of accomplished industry leaders, fostering meaningful discussions and exchanging ideas that are driving the future of the bioconjugates industry. This experience has been invaluable, providing us with fresh insights and inspiration that will fuel our ongoing commitment to innovation and growth. As we look ahead, we are excited to deepen these connections and explore new opportunities for collaboration. Let’s continue the conversation and unlock the potential of working together. Reach out to us anytime: https://lnkd.in/eCgHTVqf #SAPAGP2025AC #conjugate #conjugates #bioconjugation #bioconjugate #bioconjugates #adc #adcs #antibodydrugcongugate #antibodydrugcongugates #cmc #cdmo #crdmo #biomanufacturing #bioprocessing #cmc

Dr. Jimmy Li Shines at the 2025 SAPA-GP Annual Conference! This week at the 2025 SAPA-GP Annual Conference. During the ADC-focused session co-organized by the?Chinese Antibody Society and?SAPA-GP (Sino-American Pharmaceutical Professionals Association -Greater Philadelphia), Dr.?Jimmy Li, CEO of WuXi XDC, delivered an insightful presentation titled “Accelerating the Development of ADCs from Concept to BLA.” His talk sparked lively and engaging discussions among the audience, highlighting the critical role of innovation and collaboration in advancing ADC development. We extend our heartfelt gratitude to everyone who attended Dr. Li’s presentation—your support and enthusiasm are truly appreciated. If you’d like to explore how we can support your bioconjugate projects, we’d love to connect. Reach out to us here:?https://lnkd.in/eCgHTVqf #SAPAGP2025AC?#conjugate?#adc #bioconjugate #cdmo #cro

??Highlights from the ADC Asia Congress 2025 IMAPAC and Biologics Manufacturing Asia 2025! The exhilarating ADC Asia Congress 2025 and Biologics Manufacturing Asia 2025 were overflowing with innovation and abuzz with intellectual clashes! Dr. Jun Hu, Vice President, Head of Client Enabling Center of Excellence & Head of Singapore Site Management at WuXi XDC, delivered an insightful and thought-provoking presentation titled “Accelerate Bioconjugate Development with WuXi XDC’s Fully Integrated Capabilities and Expanding Global Capacity.” Dr. Hu highlighted the rapid growth and immense potential of ADC and XDC development in the global pharmaceutical industry, and then showcased WuXi XDC’s integrated service platform and innovative technologies, which serve as a powerful engine to accelerate bioconjugate development. Additionally, he also shared WuXi XDC’s ongoing efforts to expand its global footprint, ensuring enhanced support for partners worldwide. During the WuXi BioInnovate Luncheon at Biologics Manufacturing Asia 2025, Dr. Hu hosted a panel session on “Overcoming CMC Bottlenecks: The Future of Manufacturing Strategies.” The panel engaged in a lively discussion about the most formidable CMC bottlenecks that biopharmaceutical companies encounter during the drug development process. They also explored Technology Innovation and how to identify bottlenecks early and, through collaboration, how to evaluate/select appropriate external partners when dealing with CMC bottlenecks and help reduce risks and costs in drug development and commercialization. We extend our heartfelt gratitude to everyone who participated in our session and engaged in those rich discussions. Your engagement and interest are deeply appreciated. Let’s stay connected and explore how we can support your bioconjugate development needs. Reach out to us now: https://lnkd.in/eCgHTVqf #ADCAsia #conjugate #bioconjugate #antibodydrugcongugate #cmc #cdmo #crdmo #biomanufacturing #bioprocessing

?? Join Us for an Exclusive Webinar on Accelerating ADC & XDC Development with Novel Linker Technologies！Register now to secure your spot: https://lnkd.in/gYv8Cnyw Mark your calendars for March 27th and don’t miss our upcoming webinar: “Bridging ‘Small’ Molecules with ‘Big’ Molecules: Accelerating ADCs & XDCs Discovery and Development with Novel Linker Technologies.” Led by Dr. Jingjie Huang, this session is a must-attend for anyone exploring the cutting edge of linker/connector technologies. Dr. Huang will dive into innovative linker technologies that can modulate the physicochemical properties of ADCs and XDCs, enhancing their druggability and significantly accelerating discovery and development timelines. This is your opportunity to gain valuable insights and stay ahead in the rapidly evolving field of bioconjugates. ?? Webinar: Bridging “Small” Molecules with “Big” Molecules: Accelerating ADCs & XDCs Discovery and Development with Novel Linker Technologies ?? Speaker: Dr. Jingjie Huang, Head of Payload-Linker Discovery Service, WuXi XDC ?? March 27, 11:00 AM EDT, 4:00 PM CET #linker #conjugate #conjugates #bioconjugation #bioconjugate #bioconjugates #adc #adcs #antibodydrugcongugate #antibodydrugcongugates #cmc #cdmo #crdmo #biomanufacturing #bioprocessing

Join us in celebrating WuXi XDC's spectacular triumphs at the 2025 Asia - Pacific Biopharma Excellence Awards！IMAPAC WuXi XDC has been recognized with four prestigious awards: ?? Best ADC CDMO in China ?? Best ADC CDMO in Asia ?? Best ADC CRO in Asia ?? Best ADC Platform Technology We are honored to receive these prestigious awards, which not only reaffirm our team’s relentless pursuit of excellence and innovation in the ADC field but also underscore our dedication to delivering world-class services that empower our clients to bring novel therapies to patients worldwide. Looking ahead, WuXi XDC will continue to support our clients and advance the innovation and progress of the global bioconjugate industry！ #conjugate #bioconjugate #antibodydrugcongugate #cmc #cdmo #crdmo #biomanufacturing #bioprocessing